Non-Muscle Invasive Bladder Neoplasms

Oncology·MeSH: Non-Muscle Invasive Bladder Neoplasms

6 drugs in development·3 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
mitomycin c	GH Research PLC (GHRS)
MMC	Merus N.V. (MRUS)
tar-200	GH Research PLC (GHRS)
TAR-200	CG Oncology, Inc. (CGON)
tar-210	GH Research PLC (GHRS)
TAR-210	Merus N.V. (MRUS)

Compare drugs

mitomycin c vs MMC mitomycin c vs tar-200 mitomycin c vs tar-210

Frequently asked questions

How many drugs are in development for Non-Muscle Invasive Bladder Neoplasms?

BioSniper tracks 6 drugs in development for Non-Muscle Invasive Bladder Neoplasms across 3 companies.

How many clinical trials target Non-Muscle Invasive Bladder Neoplasms?

There are 7 clinical trials targeting Non-Muscle Invasive Bladder Neoplasms tracked by BioSniper.

Deep-dive into Non-Muscle Invasive Bladder Neoplasms

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Non-Muscle Invasive Bladder Neoplasms — Drugs in Development & Clinical Trials | BioSniper